Company: SHPH
Filing Date: 2025-03-31
Form Type: DEF 14A
Source: 0001641172-25-001889
Chunk: 20

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-31
Form: DEF 14A
Chunk 20
---
 grant worth $20,200 worth of RSUs in May 2023, vesting annually in one-third increments commencing on the first anniversary date of the grant of RSUs. Dr. Jung also received an initial RSU grant of 892 RSUs (112 on a post-reverse split basis) issuable under the Company’s 2018 Plan in May 2019, which RSUs vested over three years in substantially equal installments on each one-year anniversary of the agreement. Under Dr. Jung’s employment agreement, if Dr. Jung terminates her employment for “Good Reason,” as defined in the agreement, Dr. Jung is then entitled to her then applicable base salary for period of 12 months, subject to her continued compliance with certain requirements of her employment agreement. Dr. Jung accepted a reduced salary prior to the Company’s completion of its initial public offering in September 2022.

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth the beneficial ownership of our common stock held by each director and executive officer, by each person known by us to beneficially own 5% or more of our common stock and by directors and executive officers as a group, based on a total of 6,257,693 shares of common stock outstanding as ofMarch 13, 2025 .

Unless otherwise stated, the address of the persons set forth in the table is c/o Shuttle Pharmaceuticals Holdings, Inc., 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.

Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. Unless otherwise indicated, the stockholders listed in the table below have sole voting and investment power with respect to the shares indicated.

| 17 |

| Names                                         
 and addresses                                 |     | Number                   
 of shares                
 of common                
 stock beneficially owned 
 (#)                      |         |     | Percentage         
 of shares          
 of common stock    
 beneficially owned 
 (%)                |      |
| Directors and Named Executive                 
 Officers:                                     |     |                          |         |     |                    |      |
| Anatoly Dritschilo,                           
 M.D.(2)                                       |     |                          | 639,083 |     |                    | 10.2 |
| Christopher Cooper                            |     |                          |       - |     |                    |    - |
| Timothy Lorber(3)                             |     |                          |       - |     |                    |    - |
| Mira Jung, Ph